In the chaotic casino of the stock market, where fortunes are made and lost on the whims of traders and algorithms, Hims & Hers Health, Inc. (HIMS) has emerged as a standout, catching the eye of momentum investors with its dizzying 134% gain over the past year, as shown in the finance card above. This San Francisco-based health and wellness platform, launched in 2017, has carved out a niche by blending digital subscriptions with retail partnerships, offering everything from hair loss treatments to mental health support. With a Zacks Rank #1 (Strong Buy) and a Momentum Style Score of B, HIMS is riding a wave of investor enthusiasm—but can it keep surfing, or is a wipeout looming? Here’s a sharp, skeptical dive into why HIMS is a momentum darling, what’s fueling its rise, and whether it’s worth betting on, delivered with a sardonic nod to the absurdity of chasing stock market unicorns.
A Health Platform for the Digital Age
Hims & Hers Health isn’t your grandpa’s pharmacy. Since its 2017 debut, the company has built a consumer-focused platform that delivers personalized healthcare through seamless digital access. Think telehealth on steroids: subscriptions for treatments targeting men’s and women’s health, skincare, mental health, and more, paired with wholesale retail partnerships. Its dual revenue streams—online subscriptions and brick-and-mortar sales—cater to a generation that demands convenience and discretion. From erectile dysfunction meds to anxiety treatments, HIMS markets itself as a one-stop shop for modern health needs, all accessible from your smartphone.
The company’s growth has been nothing short of eye-popping. The finance card above shows HIMS stock soaring from $21.24 in July 2024 to $57.002 on July 23, 2025, a 168% jump in a year. Daily trading on July 23 saw the stock climb from an open of $50.0 to a high of $57.086, closing at $57.002, with an average of 33.7 million shares traded over the past 20 days. This kind of momentum—134% annual growth, 13.4% over the past month—has investors salivating, but it’s not just the price action that’s turning heads.
Momentum Metrics: Why HIMS Shines
Momentum investors, those adrenaline junkies who chase stocks with upward price or earnings trends, are drawn to HIMS for good reason. The finance card above confirms a 13.4% stock price increase over the past four weeks, despite a recent 8.5% dip in the last week. The Zacks Momentum Style Score of B reflects this volatility, rewarding HIMS for its strong one-month gains and consistent trading volume. The company’s VGM Score (Value, Growth, Momentum) of B further sweetens the deal, suggesting a balanced appeal for investors beyond just the momentum crowd.
Earnings are the other half of the story. One analyst raised their fiscal 2025 earnings estimate by $0.02 to $0.75 per share in the last 60 days, a sign of confidence in HIMS’ growth trajectory. The company’s average earnings surprise of 19.6%—beating expectations by nearly a fifth—adds fuel to the fire. These numbers paint a picture of a company not just riding a stock price wave but delivering on the bottom line, a rare combo in the speculative world of growth stocks.
The Bigger Picture: A Market Ripe for Disruption
HIMS’ rise isn’t just about clever marketing or a hot stock chart. The telehealth industry is booming, projected to hit $455 billion by 2030, driven by demand for accessible, stigma-free healthcare. HIMS has capitalized on this, targeting younger consumers who prefer digital solutions over waiting rooms. Its subscription model ensures steady revenue, while retail partnerships with chains like Walgreens expand its reach. The company’s focus on sensitive health issues—think hair loss, sexual wellness, mental health—has tapped into a cultural shift toward openness, making it a go-to for millennials and Gen Z.
But let’s not get too starry-eyed. The healthcare sector is a shark tank, with regulatory hurdles, competition from giants like Teladoc, and the risk of consumer fatigue. HIMS’ stock, while soaring, isn’t immune to volatility—the finance card shows a year-high of $72.98 and a low of $13.47, a rollercoaster that could spook the faint-hearted. The recent 8.5% weekly drop hints at profit-taking or market jitters, and with no dividend yield, HIMS is a pure growth play, not a safe haven.
Risks and Rewards: Is HIMS a Screaming Buy?
Momentum stocks like HIMS are a gamble, thrilling when they soar, brutal when they crash. The finance card’s one-year data—$21.24 in July 2024 to $57.002 in July 2025—shows a stock that’s defied gravity, but its lack of a P/E ratio suggests investors are betting on future growth, not current profits. The telehealth boom gives HIMS a tailwind, but competition and regulatory scrutiny could clip its wings. If the company keeps beating earnings expectations and expanding its user base, the sky’s the limit. But a single misstep—a bad quarter, a PR scandal—could send shares tumbling.
Investors eyeing HIMS should weigh its momentum against its risks. The Zacks Rank #1 and strong earnings surprises make it tempting, but momentum stocks can turn on a dime. “It’s a growth story with legs, but you need a stomach for the ride,” one analyst noted. The question isn’t just whether HIMS can keep climbing—it’s whether you can handle the inevitable dips.
The Road Ahead: Momentum or Mirage?
Hims & Hers Health is a poster child for the telehealth revolution, blending digital savvy with healthcare’s future. Its 134% annual gain, robust earnings surprises, and Zacks accolades make it a momentum investor’s dream. But with great reward comes great risk—volatility, competition, and the absence of dividends mean HIMS isn’t for the risk-averse. As it trades at $57.002, per the finance card above, the stock’s trajectory depends on its ability to stay ahead in a crowded field. For now, HIMS is a bet on a world where healthcare lives on your phone—just don’t be surprised if the ride gets bumpy.
